Oliver Hantschel
Lausanne, VD 1015, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications
Cytosolic delivery of monobodies using the bacterial type III secretion system inhibits oncogenic BCR: ABL1 signaling.
Journal: Cell communication and signaling : CCS
Published: July 08, 2024
The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib.
Journal: Leukemia
Published: May 31, 2024
Development of mirror-image monobodies targeting the oncogenic BCR::ABL1 kinase.
Journal: Nature communications
Published: April 16, 2024
Improving the pharmacokinetics, biodistribution and plasma stability of monobodies.
Journal: Frontiers in pharmacology
Published: April 15, 2024
The druggability of SH2 domains unmasked.
Journal: Nature chemical biology
Published: February 16, 2024
BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.
Journal: Blood
Published: September 14, 2023
Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl.
Journal: RSC chemical biology
Published: April 20, 2022
Tuning SAS-6 architecture with monobodies impairs distinct steps of centriole assembly.
Journal: Nature communications
Published: March 01, 2021
Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions.
Journal: HemaSphere
Published: October 27, 2020
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K.
Journal: Annals of hematology
Published: October 19, 2020
BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity.
Journal: The Journal of experimental medicine
Published: August 04, 2020
Last Updated: 09/26/2026